JAK2 and cancer: Recent studies have identified targets of miR-375 in various types of cancers, such as Yes-associated protein (YAP) in liver cancer [45], MTDH/AEG-1 in head and neck squamous cell carcinoma and hepatocellular carcinoma [46], [47], IGF1R and PDK1 in esophageal squamous cell carcinoma [48], [49], LDHB in maxillary sinus squamous cell carcinoma [50], JAK2, PDK1, and 14-3-3zeta in gastric cancer [40], [51], [52], and SP1 in cervical cancer [53].